oxybutynin has been researched along with perindopril in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Marcinkowska, J; Posadzy-Malaczynska, A; Rajpold, K; Woznicka-Leskiewicz, L | 1 |
1 review(s) available for oxybutynin and perindopril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for oxybutynin and perindopril
| Article | Year |
|---|---|
Hemodynamic and metabolic effects of estrogen plus progestin therapy in hypertensive postmenopausal women treated with an ACE-inhibitor or a diuretic.
Topics: Administration, Cutaneous; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diuretics; Drug Combinations; Drug Interactions; Estradiol; Estrogen Replacement Therapy; Female; Humans; Hydrochlorothiazide; Hypertension; Iodine Radioisotopes; Iodohippuric Acid; Norethindrone; Perindopril; Poland; Polypharmacy; Postmenopause; Progestins; Pulse Wave Analysis; Renal Plasma Flow; Time Factors; Transdermal Patch; Treatment Outcome; Vascular Stiffness | 2015 |